Pharmacokinetics and pharmacodynamics of alirocumab in patients with autosomal dominant hypercholesterolemia associated with PCSK9 gain-of-function or ApoB loss-of-function mutations

25 August 2018 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Professor Michel Krempf

Nantes (France)

8 More presentations in this session

Presentation thumbnail

Six-month treatment with novel oral anticoagulants ameliorates cerebral blood flow, as evaluated with brain perfusion SPECT.

Doctor H. Takeuchi (Ogachi, JP)

Abstract Slides Video

Presentation thumbnail

TAFI level dynamics during long-term warfarin therapy as a predictor of recurrent bleedings in a target INR

Professor N. Vorobyeva (Moscow, RU)

Abstract Slides Video

Presentation thumbnail

Evaluation of the pharmacokinetics and pharmacodynamics of subcutaneously administered dutogliptin for daily injection with granulocyte colony stimulating factor (G-CSF) for AMI

Mr D. Nix (Lexington Township, US)

Abstract Slides Video

Presentation thumbnail

Multiple ascending doses of recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results

Doctor M. Bonaca (Aurora, US)

Abstract Slides Video

Presentation thumbnail

Effects of the PAR-1 receptor antagonist vorapaxar on platelet activation and coagulation biomarkers in patients with stable coronary artery disease

Mrs R. Olie (Maastricht, NL)

Abstract Slides Video

Access the full session

Session thumbnail

Innovative drug therapies

The Event

ESC Congress 2018

25 August - 29 August 2018

You may be interested in

Congress Presentation

Where are we now? Decision-making in LDL-C lowering and CV risk

Webinar

Unmet needs in lipid management: treatment goals and how to achieve them

Webinar

New trial evidence in the field of lipid management

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources